Prolight Diagnostics publishes investorletter for March 2026
The investor letter highlights that Prolight has entered the year with several important milestones that further strengthen the position of our POC platform, Psyros™. Particularly encouraging is the progress in our ongoing funded collaboration with BRAINBox Solutions, where we have achieved highly positive results in an analytical evaluation of three biomarkers for Traumatic Brain Injury […]
Prolight reports positive Traumatic Brain Injury (TBI) biomarker results with BRAINBox Solutions, confirming broad assay potential of the Psyros™ POC platform
Prolight Diagnostics, a leader in point-of-care (POC) technology, today announces positive results from a collaboration with BRAINBox Solutions, a leader in multi-modality diagnostic and prognostic tests for traumatic brain injury (TBI). The analytic evaluation shows strong performance across a unique combination of three traumatic brain injury biomarkers, demonstrating the ease with which multiple novel markers can be transferred onto the Psyros unique single-molecule-counting platform and reinforcing its potential to […]
Prolight Diagnostics’ POC system Psyros attracted significant attention at the recently concluded international WHX Labs congress
According to an article published by BioStock, the Psyros system generated strong interest at the global WHX Labs industry exhibition in Dubai, where it was showcased by the contract manufacturer FlexMedical Solutions. Read the full article here: https://biostock.se/en/2026/03/stort-intresse-for-prolights-poc-system-i-takt-med-att-tillverkningspartnern-vaxlar-upp/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight […]
Biostock publishes an article after Prolight published its Year-End Report for 2025
Biostock publishes an article describing how Prolight Diagnostics is now rapidly transitioning from development to pilot production. With a European clinical multicentre study planned for 2026, Prolight is firmly setting its sights on a commercial launch in 2027. Read the full article here: https://biostock.se/en/2026/03/prolight-diagnostics-avslutar-2025-med-starkt-momentum/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 […]
Prolight Diagnostics publishes year-end report 2025
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, 2025 Net sales amounted to 0 (0). Other operating income amounted to 10,670 (15,317) TSEK. Operating profit (EBIT) amounted to -13,060 (1,492) TSEK Profit after tax amounted to -12,123 (2,014) TSEK. Earnings per share before […]
Biostock publishes an article describing how Prolight scales-up cartridge manufacturing
Biostock publishes an article describing how Prolight continues to make important progress in the scale-up of the manufacturing line for the system’s single-use cartridges. This is a critical step in securing the volumes required for the upcoming clinical performance study. BioStock talked to COO Karl Bullen to learn more. Read the full article here: https://biostock.se/en/2026/02/prolight-skalar-upp-tillverkningen-av-testkort/ […]
Biostock publishes an article about Prolight finalises instrument design and prepare for pilot manufacturing
Biostock publishes an article about Prolight finalises instrument design and prepare for pilot manufacturing. This marks a pivotal step towards the production of pilot units intended for the upcoming clinical performance study. BioStock reached out to Paul Monaghan, Head of Engineering, to learn more. Read the full article here: https://biostock.se/en/2026/01/prolight-slutfor-instrumentdesign-och-forbereder-for-pilottillverkning/ For further information, please contact:Ulf Bladin, […]
Prolight Diagnostics publishes investorletter for January 2026
The investor letter outlines that Prolight has continued to make important progress in the development of the Psyros platform. Progress in cartridge manufacturing scale-up, alongside continued refinement of the instrument design, further strengthens the platform as the company prepares for the commercial launch. The investor letter is available via the attached file or on the […]
Biostock publishes an article about the key milestone toward commercialisation – assay design freeze
Biostock publishes an article about Prolight Diagnostics has reached high-sensitivity troponin assay design freeze, locking in the final chemical configuration and performance characteristics. This marks a transition from the development phase to manufacturing optimization, setting the stage for the upcoming clinical performance study. Read the full article here: https://biostock.se/en/2025/12/prolight-diagnostics-nar-assay-design-freeze-for-det-hogkansliga-troponintestet-en-avgorande-milstolpe-for-psyros/ For further information, please contact:Ulf Bladin, […]
Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation
Prolight Diagnostics today announced it has reached assay design freeze for its Psyros™ point-of-care cartridge, marking a major development milestone for the Psyros platform and an important step toward commercialisation. The design freeze confirms the final assay configuration and performance characteristics, freezing the cartridge chemistry. With this milestone achieved, Prolight can now transition to the […]